Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Starboard Value, Kenvue
Kenvue needs to fix its skin, health & beauty segments, Starboard's Jeff Smith says (update)
Adds Kenvue comment. Kenvue (NYSE:KVUE) needs to focus on fixing its skin, health and beauty segments, Jeff Smith, founder and CEO of activist hedge fund Starboard Value said. "We are having conversations with them and there are signs that Kenvue is already going in the right direction,
Starboard says Kenvue's skin health segment weighing on performance
Hedge fund Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's lackluster growth is the reason for the stock's underperformance.Starboard Chief Investment Officer Jeffrey Smith said there is an opportunity to improve revenue growth and margins at the segment which has the Neutrogena and Aveeno brands.
Starboard Targets Another Health Company. Why Kenvue Is in Its Sights.
Tylenol, Listerine and Band-Aid maker Kenvue is the latest in the health related sector to attract an activist investor. And not just any corporate agitator, Starboard Value, which in recent days targeted pharma giant Pfizer.
8h
Kenvue's Double Catalysts: Starboard Stake and Dividend Announcement
Kenvue has a formidable lineup of well-known consumer health brands, such as Aveeno, Tylenol, Band-Aid, Zirtec, Listerine, ...
5h
10 Analysts Have This To Say About Kenvue
In the assessment of 12-month price targets, analysts unveil insights for Kenvue, presenting an average target of $24.1, a ...
BioSpace
9h
Activist Investor Starboard Takes Aim at J&J Spinoff Kenvue on Heels of $1B Stake in Pfizer
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...
9h
Kenvue, Inc.: Strong Brand Portfolio and Strategic Initiatives Drive Buy Rating with $27 Price Target
Kenvue, Inc. (KVUE – Research Report), the Technology sector company, was revisited by a Wall Street analyst yesterday. Analyst Anna ...
1d
Kenvue Stock Rallies After Activist Investor Takes Stake
Kenvue shares jumped premarket after The Wall Street Journal reported that Starboard Value has taken a sizable stake in the ...
1d
on MSN
Tylenol Maker Kenvue Stock Surges on Report Starboard Takes 'Sizable Stake'
Activist investor Starboard Value reportedly has taken a large stake in consumer health products maker Kenvue.
9h
Kenvue price target raised to $27 from $24 at BofA
BofA raised the firm’s price target on Kenvue (KVUE) to $27 from $24 and keeps a Buy rating on the shares. Noting that The Wall Street ...
1d
on MSN
Activist Starboard could push for Kenvue to sell some/all of its SHB business - analyst
Financial writer highlights activist investor Starboard Value's push for Kenvue (KVUE) to divest its challenged skin, ...
Wall Street Journal
10h
Starboard Focused on Struggling Kenvue Unit
Starboard Chief Jeff Smith said Tuesday that
Kenvue
, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment that he ...
FiercePharma
1d
Activist investor Starboard sets its sights on J&J spinout Kenvue: WSJ
Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has ...
1d
Kenvue, Inc. Positioned for Growth Amid Strategic Developments and Activist Influence
J.P. Morgan analyst Andrea Faria Teixeira has maintained their bullish stance on KVUE stock, giving a Buy rating on October 15. Andrea Faria ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Starboard
Jeff Smith
Boeing
Tesla
Reuters
Feedback